Comparative Pharmacology
Head-to-head clinical analysis: ANEXSIA 5 325 versus KESSO GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANEXSIA 5 325 versus KESSO GESIC.
ANEXSIA 5/325 vs KESSO-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
KESSO-GESIC is a combination analgesic containing butalbital (barbiturate), acetaminophen, and caffeine. Butalbital depresses the CNS by enhancing GABA-A receptor activity, acetaminophen inhibits COX enzymes centrally, and caffeine is a CNS stimulant that may enhance analgesia.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Adults: 2 tablets (325 mg acetaminophen + 5 mg hydrocodone per tablet) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Terminal elimination half-life is 2–4 hours in healthy adults. In hepatic impairment, half-life may be prolonged up to 8 hours; in renal impairment, minimal change.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Renal excretion of unchanged drug and metabolites: approximately 60% renal, 40% biliary/fecal. Major metabolites include glucuronide conjugates.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination